Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067582 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder and Autism, sponsored by Yamo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT05067582 is a Phase 2 study of Autism Spectrum Disorder and Autism that has completed, run by Yamo Pharmaceuticals. The registered enrollment target is 58 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (57% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05067582, a Phase 2 study of Autism Spectrum Disorder and Autism, has completed, sponsored by Yamo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of \>/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and a score of \>/= 4 on the Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization.
Conditions Studied
Interventions
- DRUG L1-79
Study Locations (8)
California
- Thompson Autism Center CHOC - Orange
- Cortica - San Rafael
Arizona
- Southwest Autism Research and Resource Center - Phoenix
Illinois
- Rush University - Chicago
Missouri
- Thompson Center for Autism and Neurodevelopmental Disorders - Columbia
New York
- Center for Autism and The Developing Brain - White Plains
Ohio
- Ohio State University - Columbus
Texas
- Red Oak Psychiatry Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067582
The ClinicalTrials.gov registry entry for NCT05067582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (57% lower). The listed sponsor is Yamo Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which L1-79 is the first listed.
NCT05067582 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05067582 about?
NCT05067582 is a clinical study titled "A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder". This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of \>/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and a score of \>/= 4 on the Clinical Global Impression of Severity of Ill...
What is the current status of trial NCT05067582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2022-01-25. Estimated completion is 2024-06-21.
What conditions does trial NCT05067582 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism.
What interventions are being tested in trial NCT05067582?
The interventions under investigation include: L1-79 (DRUG).
Who is sponsoring clinical trial NCT05067582?
This trial is sponsored by Yamo Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067582 being conducted?
This trial has 8 study locations across Arizona, California, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.